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Abstract: Doripenem is the latest carbapenem on the market to date. Although not an antibiotic 
in a new class, it offers a glimmer of hope in combating serious infections secondary to 
multidrug-resistant Gram-negative bacteria when we have not seen a new class of antibacterial, 
particularly for Gram-negative bacteria, for more than 10 years. In vitro, doripenem exhibits 
a broad spectrum of activity against Gram-positive and Gram-negative bacteria, including 
extended-spectrum β-lactamase (ESBL) and Amp-C β-lactamase producing Enterobacteriaceae 
and anaerobes. Doripenem also exhibits better in vitro activity against Pseudomonas aeruginosa 
compared to other anti-pseudomonal carbapenems. It combines the desirable activities of both 
imipenem and meropenem. It has similar activity to imipenem against Gram-positive pathogens 
and has the antimicrobial spectrum of meropenem against Gram-negative organisms. Several 
randomized clinical trials have demonstrated that doripenem is non-inferior to meropenem, 
imipenem, piperacillin/tazobactam, or levofloxacin in its efficacy and safety profile in treating 
a wide range of serious bacterial infections including intra-abdominal infection, complicated 
urinary tract infection, and nosocomial pneumonia. Due to its wide spectrum of activity and 
good safety profile it is susceptible to misuse leading to increasing rates of resistance. Judicious 
use should be considered when using doripenem as a first-line agent or drug of choice for 
serious infections. Doripenem is a well-tolerated drug with common adverse effects includ-
ing headache, nausea and diarrhea. Caution should be used in patients with hypersensitivity 
to carbapenems and adverse reactions to β-lactam agents. Dosage adjustment is needed for 
patients with renal impairment. Doripenem has demonstrated economic and clinical benefits. 
It has been shown to reduce hospital length of stay and duration of mechanical ventilation for 
intensive care unit (ICU) patients. Therefore, doripenem is a welcome addition to our limited 
armamentarium of antibiotics available to treat serious bacterial infections in hospitalized 
patients.
Keywords: doripenem, nosocomial pneumonia, intra-abdominal infections, urinary tract 
infections
Introduction
The emergence of antimicrobial resistance among Gram-negative organisms, especially 
extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, and resis-
tant Pseudomonas and Acinetobacter species, has been a significant challenge for the 
clinician.1 β-lactams are one of the most widely prescribed antimicrobial agents in the 
hospital setting. However, their use has resulted in a dramatic increase in the selection 
of β-lactamase variants, which threatens the utility of this class of antimicrobial.2 The 
development and approval of carbapenems was a milestone in addressing this situation Infection and Drug Resistance 2009:2 42
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because of their broad-spectrum activity against Gram-positive, 
Gram-negative, and anaerobic bacteria.3
Multi-drug resistant Gram-negative bacteria have been 
a significant cause of morbidity and mortality especially 
for hospitalized patients. There is an ongoing need for 
effective pharmacotherapy against these microorganisms. 
Among these are Pseudomonas aeruginosa, Acinetobacter 
spp., specifically Acinetobacter baumannii and Klebsiella 
pneumoniae. Colistin is an agent which has been used 
as empiric treatment for metallo-β-lactamase-producing 
K. pneumoniae. There are three other agents, that are either 
in development or on the market, worth mentioning that 
possess antimicrobial activity against multi-drug resistant 
Gram-negative bacteria: RO49084631/CS-023, tigecycline 
and CP3242.4
RO49084631/CS023 is a carbapenem that has demon-
strated activity against Gram-positive and Gram-negative 
aerobes and anaerobes such as methicillin-resistant Staphy-
lococcus aureus (MRSA), methicillin-resistant Staphylococ-
cus epidermidis (MRSE), penicillin-resistant Streptococcus 
pneumoniae (PRSP), β-lactamase-negative ampicillin-
resistant Haemophilus influenzae and P. aeruginosa. 
Tigecycline is a bacteriostatic agent which inhibits protein 
translation. It possesses activity against MSSA, MRSA and 
MRSE, as well as vancomycin-resistant Enterococcus spp. 
Lastly, CP3242 is an inhibitor of metallo-β-lactamases. It 
demonstrated potency against MBL-producing P. aerugi-
nosa in vivo and in vitro when combined with biapenem, 
imipenem, meropenem or ceftazidime.4
Because the carbapenems have the broadest antibacterial 
spectrum of activity, there is concern that abuse or overuse 
of this class of antibiotic will lead to the development of 
resistance.5 Various methods have been suggested in an effort 
to either delay resistance selection or to enhance activity 
against resistant strains including the co-administration of an 
aminoglycoside with doripenem1 and prolonging antibiotic 
infusion,6 respectively.
Rising rates of antibiotic-resistance among bacteria in 
the hospital setting highlight the need for new therapeutic 
options,7 in particular, for the treatment of MRSA and other 
organisms which are resistant to doripenem. Although 
doripenem offers a glimmer of hope in combating serious 
hospital infections, the fact remains that only ten new antibi-
otics have been approved within the past ten years, of which 
only two have been truly novel. This highlights the growing 
concern over the present drought in the antibiotic research 
and development pipeline and, therefore, the need for further 
emphasis on drug discovery.
Chemistry
Doripenem is the newest member of the carbapenems on 
the US market. Human kidneys produce dehydropeptidase-1 
(DHP-1), which can hydrolyze and inactivate imipenem. 
However, the addition of a methyl chain on the nucleus 
of doripenem increases its stability against DHP-1.8 This 
methyl side chain is also found in meropenem and ertapenem. 
Doripenem has a sulfamoly-aminomethyl-pyrrolidinylthio 
side chain replacing the dimethyl-carbamoyl-pyrrolidinylthio 
side chain in position 2 of meropenem. This unique side chain 
of doripenem enhances its potency against Gram-positive 
bacteria, such as methicillin-sensitive S. aureus, while main-
taining its activity against Gram-negative bacteria.4
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Figure 1 Chemical structure of doripenem.Infection and Drug Resistance 2009:2 43
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Mode of action
Like other β-lactams and carbapenems, doripenem exhibits 
its antimicrobial effects by binding penicillin binding proteins 
(PBP) that are necessary to maintain the bacterial cell wall 
leading to cell death.9,10 Doripenem binds to PBP-2, PBP-3, 
and PBP-4.10 Affinities for PBPs vary by species.5
Pharmacodynamics
The bactericidal effects are nonconcentration dependent; the 
longer the time above the minimum inhibitory concentration 
(T  MIC), the greater the effect.5,11–14 The proportion of time 
during the dosing interval, where the concentration is greater 
than the MIC for non-protein bound carbapenems, correlates 
to in vivo activity of the drug for a specific organism.15 In 
general, for carbapenems, a T  MIC of 20% results in a 
bacteriostatic effect with the maximum bactericidal effect at 
40%.4,16 Katsube et al studied the %T  MIC for doripenem 
against three strains of P. aeruginosa. They showed a static 
effect with a T  MIC at 25%, 23.9% and 39.8% and a 
2-log killing effect at 28.1%, 29.5% and 49.6% and a 90% 
maximum killing effect at 36.5%, 46.8% and 80.7% for 
respective strains.17
Spectrum of activity
Doripenem has a broad spectrum of activity against 
Gram-positive, Gram-negative and anaerobic bacteria 
including multidrug-resistant strains, most notably the 
ESBL and Amp-C β-lactamase producing Gram-negative 
organisms.2,5,9–11,13,14,18 It has comparable antimicrobial 
activity to meropenem and imipenem.2,13,14 In vitro activity 
against P. aeruginosa, Acinetobacter spp., ceftazidime-
resistant bacteria and selected ESBL-producing bacteria 
show lower MICs with doripenem. For example, Fritsche 
et al through analysis of the antimicrobial activity of 16,008 
clinical isolates, demonstrated that doripenem was the most 
active agent (MIC90 8 mg/L) among the carbapenems tested 
against wild type P. aeruginosa. In this study, the MIC90 
of meropenem and ertapenem were found to be 16 mg/L 
and 8 mg/L, respectively. However, the clinical relevance 
is unknown.2,19 Doripenem has in vitro activity against 
H. influenzae (including β-lactamase positive isolates) and 
Moraxella catarrhalis.2,18
As with other carbapenems, doripenem is not active 
against Enterococcus faecium or MRSA because of alteration 
of the bacteria’s PBPs leading to poor binding affinity.13, 20
Although doripenem is stable against most β-lactamases, 
some carbapenemases will affect its activity. The Ambler’s 
class B metallo-β-lactamase is a potent cabapenemase 
which is intrinsically produced by Stenotrophomonas 
maltophilia, resulting in resistance to carbapenems, includ-
ing doripenem. However, some strains of Gram-negative 
bacteria, such as P. aeruginosa, Acinetobacter baumannii and 
Enterobacteriaceae, are resistant to doripenem by producing 
Ambler’s class A enzymes, class B metallo-β-lactamases 
(IMP, VIM, SPM), class D enzymes (OXA group) and KPC 
enzymes.2,15,18,21, 22
Recently, the incidence of carbapenemase-producing 
Enterobacteriaceae (CRE) including Klebsiella spp. has 
been increasing globally. Serine β-lactamase KPC is the 
main carbapenemase produced by CRE. Because CRE are 
highly resistant to doripenem (MIC 8 to 64 µg/ml) and 
other carbapenems, there is no reliable antibiotic treatment 
for patients infected with CRE, thus, causing high morbidity 
and mortality in hospitalized patients.23,24
P. aeruginosa and other Gram-negative bacteria can 
confer resistance to doripenem by overexpressing multidrug 
Table 1 In vitro susceptibility of common pathogens to doripenem2,4,10
Gram-positive microorganisms
Streptococcus constellatus
Streptococcus intermedius
Streptococcus agalactiae Streptococcus pneumoniae
Streptococcus pyogenes
Methicillin-susceptible Staphylococcus aureus
Gram-negative microorganisms
Acinetobacter baumannii
Citrobacter freundii
Enterobacter aerogenes
Enterobacter cloacae
Escherichia coli (including ESBL confirmed spp.)
Haemophilus influenzae (including β-lactamase producing strains)
Klebsiella pneumoniae (including ESBL confirmed spp.)
Klebsiella oxytoca
Moraxella catarrhalis
Morganella morganii
Proteus mirabilis
Pseudomonas aeruginosa
Serratia marcescens
Anaerobic microorganisms
Bacteroides caccae
Bacteroides fragilis
Bacteroides thetaiotaomicron
Bacteroides uniformis
Bacteroides vulgatus
Peptostreptococcus micros
Abbreviation: eSBL, extended spectrum β-lactamase.Infection and Drug Resistance 2009:2 44
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efflux pump system called MexA-MexB-OprM, resulting in 
decreased antibiotic concentration at target sites.25 These bac-
teria can also exhibit resistance to many antibiotics through 
a combination of increased permeability, efflux system and 
production of β-lactamases. One way of increasing perme-
ability is through loss of OprD porin of the organisms. The 
sensitivity of P. aeruginosa to imipenem is reduced by loss 
of OprD porin; however, Mushtaq and co-workers demon-
strated that a combination of loss of OprD porin and presence 
of efflux pump is necessary for P. aeruginosa to develop 
resistance against meropenem and doripenem.26
Susceptibility to doripenem was defined as 0.5 µg/mL for 
Enterobacteriaceae, 2 µg/mL for P. aeruginosa, 1 µg/mL 
for Acinetobacter baumannii and anaerobes, and  0.12 µg/mL 
for Streptococcus anginosus group. However, when suscep-
tibility reports of doripenem are not available, Jones and 
colleagues reported carbapenems (imipenem, meropenem, 
ertapenem), oxacillin and ampicillin can be used as surrogate 
testing agents with high absolute categorical agreement (89.1% 
to 100%) and negligible false-susceptible error ( 0.1%).27
Pharmacokinetics
Among a group of healthy study participants given a single 
1-hour intravenous infusion of 500 mg, the mean plasma 
concentration max (Cmax) was 23 µg /mL and the mean area 
under the curve (AUC) was 36.3 µg⋅h/mL.
Doripenem has linear kinetics when infused intravenously 
over one hour over a dose range of 500 mg to 1 g.10 It has 
an 8.1% average binding to plasma proteins with a median 
volume of 16.8 L (8.09 tp 55.5 L) among healthy partici-
pants.10 Doripenem also demonstrates significant penetration 
into several body fluids and tissues, including peritoneal and 
retroperitoneal fluids, urine, bile and the gallbladder.10
Doripenem is metabolized by dehydropeptidase-I to an 
inactive metabolite (doripenem-M1). It does not interact with 
the cytochrome P450 (CYP450) enzymes as either a substrate 
or an inhibitor.10 In healthy volunteers, 15% of the dose was 
recovered in urine as metabolite within 48 hours.10
The approved dosing and administration of doripe-
nem is 500 mg every 8 hours infused over one hour for 
patients 18 years of age for complicated intra-abdominal 
infections (cIAIs) or complicated urinary tract infections 
(cUTIs).10 Doripenem is eliminated primarily by the kidneys 
via glomerular filtration and active tubular secretion with 
70% recovered in the urine as unchanged drug.10 The half-
life of doripenem is approximately 1 hour among healthy 
adults.10 Doripenem dose adjustment for renal impairment 
is required.
Dosage adjustments are not recommended for the elderly 
nor should they be based on gender.10 Doripenem is hemodia-
lyzable with systemic levels reduced by 48% to 62%.4 However, 
the manufacturer has not given recommendations for dose 
adjustments in hemodialysis due to insufficient information.10
Doripenem is stable in 0.9% sodium chloride for eight hours 
at room temperature and may exceed twelve hours.4,10,14
Efficacy and safety of doripenem
Doripenem was approved by the United States Food and 
Drug Administration (FDA) in October 2007 for the treat-
ment of cIAIs and cUTIs, including pyelonephritis.4 The 
manufacturer (Johnson & Johnson Pharmaceutical Research 
and Development) of doripenem (Doribax®) has submitted 
an application for the additional indication of nosocomial 
pneumonia (NP), including ventilator-associated pneumonia, 
which is currently under FDA review.28 Doripenem is indi-
cated for NP in the European Union.11
The following sections will discuss the clinical efficacy and 
safety of doripenem in treatment of cIAIs, cUTIs and NP.
Complicated intra-abdominal  
infections (cIAI)
Two Phase 3 trials were conducted to establish the efficacy and 
safety of doripenem in treating intra-abdominal infections.
Lucasti et al29 conducted a prospective, multicenter, 
double blind trial which compared intravenous (IV) doripenem 
500 mg every 8 hours (n = 237) with IV meropenem 1000 mg 
every 8 hours (n = 239). Patients in both groups could be 
switched to oral amoxicillin/clavulanate after adequate 
clinical improvement was achieved. The primary endpoint 
was to compare the clinical cure rates of doripenem versus 
meropenem in treatment of cIAIs in hospitalized patients at the 
test of cure (TOC) visit. The TOC visit could range from 21 to 
60 days after completing the study drug therapy. The second 
Table 2 Pharmacokinetic properties of doripenem following a 
single 1-hour intravenous infusion of a 500 mg dose administered 
to healthy participants (N = 24)10
Property Value for doripenem
Mean Cmax 23 µg/mL
Mean AUC 36.3 µg⋅h/mL
Protein binding 8.1%
volume of distribution 16.8 L
Metabolism Dehydropeptidase-I
Half-life ∼1 hour
Abbreviations: Cmax, maximum concentration; AUC, area under the curve.Infection and Drug Resistance 2009:2 45
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endpoints were to compare (1) clinical responses at the end 
of IV treatment, at an early follow-up visit; (2) microbiological 
responses at the end of IV treatment, early follow-up and TOC 
visits; and (3) safety profiles.
Comparison of clinical cure rates at the TOC visit 
showed doripenem was non-inferior to meropenem. Micro-
biological eradication (ME) rates for common pathogens 
(eg, Escherichia coli, P. aeruginosa) were not statistically 
different between the treatment groups.
The most common treatment related adverse reactions 
were nausea, fever, diarrhea, anemia and phlebitis for both 
carbapenems. There was no significant difference with regard 
to their safety profile.
Another prospective, multicenter, double blind trial con-
ducted by Malafaia and colleagues30 was similar in design 
to the study by Lucasti et al. The researchers compared IV 
doripenem 500 mg every 8 hours a day versus meropenem 
1000 mg every 8 hours a day in treating intra-abdominal 
infections. Patients in both groups were allowed to switch 
to oral amoxicillin/clavulanate after completing a minimum 
of 9 doses of IV antibiotics.
Four hundred and eighty-six patients were randomized 
to either the doripenem group or the meropenem group. The 
patients were first assessed for early efficacy and safety 7 to 
14 days after the end of therapy. They were then assessed for 
microbiologic and clinical efficacy (CE) 28 to 42 days after the 
TOC visit. The primary endpoint was to compare clinical cure 
rates in the ME group at the TOC visit and in the microbio-
logical modified intent-to-treat (mMITT) group. Secondary 
endpoint was to compare clinical cure rates in the CE group 
and microbiologic response in the ME group at the TOC visit. 
Doripenem was shown to be non-inferior to meropenem in 
achieving both primary and secondary endpoints.
Safety profile for both carbapenems was very similar and 
there were no deaths during the study that were attributable 
to any of the antibiotics. The most common adverse reac-
tions related to doripenem were nausea, vomiting, diarrhea 
and anemia.
In essence, the outcomes of Malafaia’s study were 
similar to Lucasti’s with respect to efficacy and adverse 
drug events.
Complicated urinary tract infections
A Phase 3, prospective, multicenter, randomized double-blind 
trial conducted by Naber et al31 compared IV doripenem 500 mg 
every 8 hours versus IV levofloxacin 250 mg every 24 hours in 
the treatment of cUTI. Both antibiotics were administered as a 
1-hour IV infusion. Seven hundred and fifty-three patients were 
enrolled, 377 in the doripenem arm and 376 in the levofloxacin 
arm. The primary endpoint is to determine the microbiologic 
response at the TOC visit, which is defined as 6 to 9 days 
after the completion of study drug therapy following a 10-day 
treatment regimen. The secondary objective is to determine the 
clinical response at the TOC visit. After 9 doses of IV study 
drug therapy, patients could be switched to oral levofloxacin 
if the patient became afebrile, and had no signs or symptoms 
of cUTI and negative urine culture.
Analysis of the efficacy results revealed that doripenem 
was non-inferior to levofloxacin in microbiological and 
clinical effectiveness. Doripenem was effective against 
major causative organisms of cUTIs including; E. coli, 
Proteus mirabilis, and K. pneumoniae. Analysis of safety data 
indicated doripenem was well tolerated by patients without 
demonstrating serious adverse reactions, such as seizures. 
The most common side effect for this study was headache.
Another randomized, controlled, double-blind trial 
(n = 155) was conducted in Japan by Kamidono et al32 to 
compare the efficacy of IV doripenem 250 mg every 12 hours 
(n = 76) versus IV meropenem 500 mg every 12 hours (n = 79) 
in patients with cUTIs requiring parenteral antibiotic therapy. 
All subjects were adult inpatients aged 20 to 79 years of age 
who demonstrated both pyuria and bacteriuria. Clinical effi-
cacy was 93.4% (71/76) in the doripenem group versus 92.4% 
(73/79) in the meropenem group. The bacteriologic response 
was 95.9% (94/98) in the doripenem group versus 96% 
(101/105) in the meropenem group. The authors concluded 
that doripenem was non-inferior to meropenem, clinically 
and bacteriologically. In regard to safety data, adverse drug 
reactions occurred in 4.3% of the doripenem group and 4.0% 
of the meropenem group. These results demonstrated that both 
doripenem and meropenem have a high safety profile.
Nosocomial pneumonia
Several clinical studies have been conducted to examine the 
efficacy and safety of doripenem versus other antibiotics on 
the market in treating NP.
The first study was a Phase 3, multicenter, prospective, 
randomized, open-label study conducted by Réa-Neto et al33 
to compare IV doripenem q8h 60-minute infusion versus 
intravenous piperacillin/tazobactam 4.5 g every 6 hours 30-
minute infusion in non-ventilated NP patients and patients 
with early-onset ventilator-associated pneumonia (VAP). 
Four hundred forty-eight adult patients were enrolled, 225 
were randomized to the doripenem group and 223 to the 
piperacillin/tazobactam group. Randomization was stratified 
by mechanical ventilation association, severity of illness, and Infection and Drug Resistance 2009:2 46
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geographic region. After 72 hours of  IV study drug therapy, 
the patients were allowed to switch to oral levofloxacin 
750 mg daily if they met all the criteria, which indicated 
sufficient clinical improvement.
The primary endpoint was to compare the clinical cure 
rate of IV doripenem versus IV piperacillin/tazobactam at 
the TOC visit in patients with NP. The TOC visit was con-
ducted 7 to 14 days after completion of study drug therapy. 
Secondary endpoint was to compare the clinical response rate 
and microbiological response rate of IV doripenem versus 
IV piperacillin/tazobactam and to compare the safety profile 
of the two antibiotics.
Clinical cure rates for meropenem and piperacillin/tazo-
bactam were 67.6% and 67.4%, respectively. Microbiological 
cure rate was 84.5% for doripenem versus 80.7% for piper-
acillin/tazobactam. The primary endpoint analysis revealed 
that doripenem was non-inferior to piperacillin/tazobactam 
in efficacy in treatment of NP. Secondary endpoint analyses 
demonstrated that doripenem was clinically and therapeuti-
cally noninferior to piperacillin/tazobactam.
The most common adverse drug reactions in the doripe-
nem group were increased liver enzymes, thrombocythemia 
and diarrhea. Adverse events were comparable between 
doripenem (16.1%) and piperacillin/tazobactam (17.6%), and 
the authors concluded that both doripenem and piperacillin/
tazobactam have high safety profiles.
The second study was a Phase 3 prospective, multicenter, 
randomized open-label trial conducted by Chastre et al34 to 
compare IV doripenem 500 mg every 8 hours 4-hour infu-
sion versus IV imipenem 500 mg every 6 hours 30-minute 
infusion, or 1000 mg every 8 hours 60-minute infusion in 
treating adult patients with VAP. Duration of treatment was 
7 to 14 days for both antibiotics. Number of patients enrolled 
was 531, 264 in the doripenem group and 267 in the imi-
penem group. Randomization was stratified by duration of 
mechanical ventilation, severity of illness and by region.
The study design for patients in the doripenem group to 
receive 4-hour infusion could be based on the Psathas et al 
study,35 which was able to demonstrate that, in vitro, doripe-
nem was stable for up to 12 hours in 0.9% NaCl solution at 
room temperature.
The primary endpoint was to compare the clinical 
response rate of IV doripenem versus IV imipenem at the 
TOC. The TOC was conducted 7 to 14 days after completion 
of study drug therapy. The secondary endpoint was to com-
pare per subject microbiological response rate, per pathogen 
microbiological outcome rate, per pathogen clinical cure rate, 
and the safety profile of the two antibiotics.
Clinical cure rates in the ME group for doripenem and 
imipenem were 69.0% and 64.5%, respectively. Favorable 
per-subject microbiological response rate in the ME at TOC 
visit for doripenem and imipenem was 73.3% and 67.3%, 
respectively. The results demonstrated that doripenem was 
not inferior to imipenem in efficacy in treating VAP.
The most common drug related adverse reactions with 
doripenem were increased liver enzymes (4.6%), diarrhea 
(1.9%), rash (1.9%), and vomiting (1.5%). The incidence of 
adverse events was 17.2% for doripenem versus 17.5% for imi-
penem. Thus, doripenem was generally well tolerated and the 
safety profiles of doripenem and imipenem were comparable.
A Japanese study examined the clinical efficacy and safety 
of IV doripenem 250 mg every 12 hours versus IV merope-
nem 500 mg every 12 hours in a randomized, double-blind 
trial in treatment of patients with respiratory infections.36 The 
majority of the patients in both groups were patients with 
bacterial pneumonia (131/193), and the rest were patients with 
concomitant chronic respiratory tract and other lung diseases 
(eg, chronic bronchitis, bronchietasis, bronchial asthma or 
emphysema) (62/193). Both groups were treated for 7 days. 
One hundred and ninety-three patients were evaluated for 
clinical efficacy. Clinical efficacy was 92.7% and 90.7% in 
the doripenem group and the meropenem group, respectively. 
The authors concluded that doripenem demonstrated nonin-
feriority to meropenem in clinical efficacy. For safety profile, 
218 patients were available for data analysis. The incidence of 
nonlaboratory adverse drug reactions was 8.1% in the doripe-
nem group and 6.5% in the meropenem group. For laboratory 
adverse drug reactions, the incidence was 23.4% and 25.5% in 
the doripenem group and meropenem group, respectively. The 
authors found no significant difference between nonlaboratory 
and laboratory adverse drug reaction incidence.
In summary, although doripenem has not yet been 
approved by the FDA for treating NP, the prospective clinical 
trials mentioned above found that doripenem was not inferior 
to other antibacterial agents on the market for treating cIAIs, 
cUTIs and NP in terms of efficacy and adverse effects.
Table 3 Manufacturer renal dosage adjustment recommendations10
Creatinine clearance Dose
50 mL/min No dosage adjustment
30 to 50 mL/min 250 mg intravenously (over 1 hour) 
every 8 hours
10 to 30 mL/min 250 mg intravenously (over 1 hour) 
every 12 hours
Dialysis Insufficient information to make 
dosing recommendationsInfection and Drug Resistance 2009:2 47
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Safety, drug interactions, 
and tolerability
Adverse reactions
In general, doripenem is well tolerated.4,10,37 The most 
common adverse reactions reported in Phase 3 clinical trials 
included headache, nausea, diarrhea, rash, and phlebitis.20
Rare, but serious, doripenem postmarket adverse events 
reported included anaphylaxis, neutropenia, Stevens-Johnson 
Syndrome, toxic epidermal necrolysis, interstitial pneumonia, 
and seizure.10 Doripenem was noted to cause a mild elevation 
in alanine aminotransferase and aspartate aminotransferase 
enzymes.33 Doripenem has also caused pneumonitis when admin-
istered via inhalation, therefore, this route should be avoided.10
Previous carbapenems have been noted to induce seizures 
primarily via inhibition of γ-aminobutyric acid (GABA) 
receptor binding.20,29,34,38 Doripenem has low affinity to 
the GABA receptor, resulting in low potential for seizure 
induction.34 In an experiment by Horiuchi et al utilizing rats 
and dogs, doripenem did not induce seizure-like behavior 
or activity on electroencephalogram (EEG). In addition, 
doripenem did not induce convulsive activities post intra-
cerebroventricular injection.4,38 These findings are consistent 
with other Phase 3 clinical trials of doripenem.33
Safety
Doripenem should be used with caution or avoided in patients 
with previous hypersensitivity to β-lactam antibiotics. Severe 
anaphylaxis and serious skin reactions have developed in those 
patients with hypersensitivity to β-lactam antibiotics.4,10,39 
Structural similarity of the bi-cyclic core of β-lactam antibiot-
ics is thought to be the underlying cause of cross-reactivity.37,39 
A retrospective chart review concluded that carbapenem 
hypersensitivity reaction occurred in 9% to 11% of patients 
with a history of penicillin allergy and 3% to 4% in patients 
without penicillin allergy.4,37,39
Due to lack of safety and efficacy data in the pediatric popu-
lation, doripenem is only recommended for patients 18 years 
of age.10,20 Imipenem has been approved for use in neonates; 
ertapenem and meropenem in infants 3 months of age.20
In pregnancy, doripenem is classified as a category B 
medication as it did not produce teratogenic effects, ossifica-
tion, or developmental delays. Animal reproduction studies 
have failed to demonstrate a fetal risk; however, there have 
been no controlled studies in pregnant women or animal 
studies demonstrating adverse effects. Doripenem should 
be used with caution in pregnant women and should be 
administered only if there are clear indications.10
Drug interactions
Doripenem should be used with caution when administered 
concomitantly with valproic acid due to the inhibition of val-
proic acid glucuronide hydrolysis leading to sub-therapeutic 
valproic serum levels resulting in possible seizure activity.4,10 
Valproic levels should be monitored carefully with concomi-
tant doripenem use.10,20 A different antibiotic or anticonvul-
sant should be considered if the valproic level is not readily 
maintained in therapeutic range.10,20
Concomitant use of doripenem and probenecid should 
be avoided.10 Probenecid interferes with the active tubular 
secretion of doripenem resulting in an increased doripenem 
plasma concentration causing a 75% increase AUC and 
prolonged plasma elimination half life by 53%.10,20,33
Place in therapy
Generally, doripenem is well tolerated in patients with 
serious bacterial infections. The most common side effects 
include headache, nausea and diarrhea, while the most com-
monly reported laboratory abnormalities included increased 
levels of ALT and AST.14 There is less seizure potential as 
it has the lowest GABA receptor binding affinity among the 
carbapenems.34,38 Caution should be used in patients with 
known hypersensitivity to carbapenems or β-lactam agents.
Doripenem is used as a single agent for the treatment of 
cIAIs or complicated cUTIs in adult patients.18 Doripenem’s 
dosing schedule makes it fairly easy to administer in hospitals, 
nursing homes, or other skilled nursing facilities. In limited 
circumstances, doripenem may even be used for qualified 
patients requiring outpatient (home) intravenous antibiotics.
Doripenem has demonstrated a decrease in the length of 
hospital stay and time of mechanical ventilation in a Phase 3, 
randomized, open-label, noninferiority study.40 It combines the 
desirable attributes of imipenem and meropenem, which makes 
it a favorable drug against serious bacterial infections. It is 
well-tolerated and proven to be cost-effective leading to greater 
patient and hospital satisfaction. These factors make doripenem 
a broad-spectrum antibiotic that can be used to treat a wide range 
of infections while minimizing negative effects on patients.
Since carbapenems have time-dependent bactericidal 
effects, the optimal method to maximize the %T  MIC is 
to give the drug as a continuous infusion.16,41 Alternative dos-
ing strategies such as continuous or prolonged infusions of 
previous carbapenems (ie, imipenem and meropenem) have 
had limited feasibility due to their stability at room tempera-
ture for 4 to 6 hours.16 The prolonged stability of doripenem 
at room temperature may allow for prolonged infusions in an 
effort to extend the T  MIC and, therefore, enhance anti-Infection and Drug Resistance 2009:2 48
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microbial activity. Ikawa et al reported that prolonging the 
infusion time (4 hours) was more effective in increasing the 
pharmacokinetic and pharmacodynamic breakpoint to achieve 
a T  MIC of 40%.6 Van Wart et al used pharmacokinetic-
pharmacodynamic modeling to show that a higher dose of 
doripenem (1000 mg) infused over 4 hours every 8 hours was 
predicted to be effective for Gram-negative bacilli with MIC 
values of 8 mcg/mL, which would currently be considered 
carbapenem nonsusceptible (MICs,  8 µg/mL).42 Ongoing 
clinical trials are evaluating the use of this higher dose and 
prolonged infusion time for hospital-acquired pneumonia.42
Conclusions
Doripenem is a valuable drug that is being used more fre-
quently in antibiotic therapy. It has proven its efficacy against 
NP, cIAIs and cUTIs. It is currently the latest FDA approved 
carbapenem and combines the antimicrobial activity of 
meropenem against Gram-negative bacteria and imipenem’s 
action against Gram-positive organisms. Doripenem offers 
further solution to the treatment of nosocomial infections given 
its efficacy, spectrum, and β-lactamase stability compared to 
other carbapenems.2 Present data suggests that doripenem can 
play an important role in patients with serious nosocomial 
infections in the setting of multidrug resistant Gram-negative 
organisms where P. aeruginosa is prevalent.4
The efficacy and tolerability of doripenem in adults with 
cIAIs, cUTIs, and VAP, has been shown in several early 
trials.18,29,34
A recent study comparing resource utilization with 
doripenem versus imipenem from a hospital perspective 
among patients with VAP has demonstrated a significantly 
shorter length of stay and time on mechanical ventilation 
with doripenem. This study suggests that doripenem use 
may be economically and clinically beneficial to hospitals 
and patients.40 These desirable effects make doripenem a key 
drug to treat serious bacterial infections.
Doripenem’s broad-spectrum of activity, its reported effi-
cacy, and cost-effectiveness may make this the drug of choice 
for serious bacterial infections. Current clinical trials and in 
vitro susceptibilities have shown that doripenem may be use-
ful for adult patients with serious infections that require broad 
spectrum antibiotics against multidrug resistant pathogens.43
In vitro testing demonstrated that doripenem exhibits low 
potential for selecting for resistance.14 One recent study exam-
ined 34 carbapenem-resistant P. aeruginosa isolates and found 
that doripenem displayed the lowest rates of resistance with an 
MIC50 value of 8 mg/mL.19 Doripenem may soon be widely used 
in the hospital setting to treat serious polymicrobial infections.
However, doripenem’s broad spectrum of activity and 
safety profile make it susceptible to misuse and overuse.44 
This can result in higher resistance rates to common Gram-
negative bacteria such as P. aeruginosa. Care should, there-
fore, be taken when considering doripenem as a first-line 
drug. Development of in vivo resistance against doripenem 
should be further investigated.4 Local hospital epidemiology 
and bacterial resistance patterns should be key factors in 
making clinical use decisions.
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